Eli Lilly Enters Strategic Research Collaboration with Abbisko Therapeutics, Potential $1.9 Billion in Payments
Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment
Positive
Importance
7
Price
$1,107.48
Mkt Cap
$1.043T
52W Low
$623.78
52W High
$1,182.73
52W Position
78% above low
Off High
6.4% below high
Rel. Volume
1.0× avg
Market data snapshot near publication time
LLY sits 78% above its 52-week low of $623.78.
Summary
Eli Lilly has entered a strategic research collaboration and license agreement with Abbisko Therapeutics, focusing on multiple innovative medicine targets. Under the terms, Abbisko is eligible for payments up to $1.9 billion. This agreement expands Eli Lilly's R&D pipeline and potential future drug development.
At the time of this announcement, LLY was trading at $1,107.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.
Price Chart
LLY - Latest Insights
LLY
Nov 18, 2026, 3:04 PM EST
Price at Filing:
$1,381.18
Real-time Price:
$1,348.06
Change:
-$33.12 (-2%)
Market Cap:
$1.267T
LLY
Nov 17, 2026, 11:18 AM EST
Price at Filing:
$1,416.23
Real-time Price:
$1,348.06
Change:
-$68.17 (-5%)
Market Cap:
$1.267T
LLY
Nov 16, 2026, 6:52 AM EST
Price at Filing:
$1,455.36
Real-time Price:
$1,348.06
Change:
-$107.30 (-7%)
Market Cap:
$1.267T
LLY
Nov 12, 2026, 8:30 AM EST
Price at Filing:
$1,452.70
Real-time Price:
$1,348.06
Change:
-$104.64 (-7%)
Market Cap:
$1.267T
LLY
Nov 12, 2026, 3:00 AM EST
Price at Filing:
$1,447.85
Real-time Price:
$1,348.06
Change:
-$99.79 (-7%)
Market Cap:
$1.267T